Drug Profile
GSK 1521498
Alternative Names: 1521498; GSK-1521498Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Obesity therapies; Small molecules
- Mechanism of Action Opioid mu receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- No development reported Cocaine-related disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cocaine-abuse in United Kingdom (PO)
- 27 Jun 2015 Phase-II development for Obesity is ongoing in the United Kingdom
- 31 Dec 2012 GlaxoSmithKline initiates enrolment in a phase I trial in healthy volunteers (with obesity and regular alcohol intake) in United Kingdom (NCT01738867)